Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.2000
- TODAY'S CHANGE (%)0.0100 (0.3135%)
- Bid / Lots3.2000/ 6
- Ask / Lots3.2200/ 4
- Open / Previous Close3.2100 / 3.1900
- Day Range
- 52 Week Range
- Volume77,864
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 4664 | 3.21 |
| 09:34 ET | 1278 | 3.24 |
| 09:36 ET | 400 | 3.26 |
| 09:38 ET | 400 | 3.27 |
| 09:39 ET | 100 | 3.265 |
| 09:41 ET | 620 | 3.265 |
| 09:43 ET | 2741 | 3.2301 |
| 09:45 ET | 400 | 3.25 |
| 09:50 ET | 500 | 3.28 |
| 09:52 ET | 1607 | 3.27 |
| 09:54 ET | 300 | 3.28 |
| 09:56 ET | 2000 | 3.27 |
| 09:57 ET | 100 | 3.265 |
| 09:59 ET | 300 | 3.28 |
| 10:03 ET | 500 | 3.28 |
| 10:06 ET | 500 | 3.28 |
| 10:08 ET | 8157 | 3.3 |
| 10:10 ET | 700 | 3.29 |
| 10:14 ET | 320 | 3.3 |
| 10:15 ET | 500 | 3.3 |
| 10:19 ET | 1800 | 3.3 |
| 10:24 ET | 1032 | 3.32 |
| 10:26 ET | 600 | 3.32 |
| 10:28 ET | 803 | 3.3183 |
| 10:30 ET | 1887 | 3.32 |
| 10:32 ET | 1303 | 3.3262 |
| 10:33 ET | 462 | 3.33 |
| 10:35 ET | 350 | 3.33 |
| 10:37 ET | 3145 | 3.3 |
| 10:39 ET | 409 | 3.3 |
| 10:42 ET | 1297 | 3.31 |
| 10:44 ET | 2100 | 3.31 |
| 10:46 ET | 350 | 3.3035 |
| 10:48 ET | 700 | 3.31 |
| 10:51 ET | 1417 | 3.31 |
| 10:53 ET | 800 | 3.32 |
| 10:55 ET | 300 | 3.315 |
| 10:57 ET | 1000 | 3.33 |
| 11:02 ET | 700 | 3.33 |
| 11:04 ET | 1323 | 3.33 |
| 11:08 ET | 191 | 3.32 |
| 11:09 ET | 1666 | 3.32 |
| 11:11 ET | 100 | 3.32 |
| 11:13 ET | 200 | 3.31 |
| 11:20 ET | 3957 | 3.3 |
| 11:22 ET | 400 | 3.29 |
| 11:26 ET | 816 | 3.29 |
| 11:29 ET | 300 | 3.29 |
| 11:31 ET | 2318 | 3.27 |
| 11:33 ET | 544 | 3.28 |
| 11:38 ET | 100 | 3.26 |
| 11:42 ET | 600 | 3.255 |
| 11:44 ET | 500 | 3.25 |
| 11:47 ET | 900 | 3.23 |
| 11:54 ET | 1500 | 3.22 |
| 11:56 ET | 200 | 3.21 |
| 11:58 ET | 100 | 3.21 |
| 12:00 ET | 100 | 3.21 |
| 12:02 ET | 200 | 3.2 |
Jun 25, 2024
Jun 20, 2024
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 189.5M | -6.3x | --- |
Rani Therapeutics Holdings Inc | 188.6M | -2.8x | --- |
Immutep Ltd | 288.3M | -7.4x | --- |
Design Therapeutics Inc | 193.2M | -3.4x | --- |
Trevi Therapeutics Inc | 181.7M | -8.0x | --- |
Prelude Therapeutics Inc | 197.7M | -1.9x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $189.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
